Clinical trial news

Discussion

A Phase 2 clinical trial investigating a potential treatment, CK-2127107, in people with spinal muscular atrophy (SMA), ages 12 years and older, is currently recruiting patients in the U.S. with varying degrees of disease severity (Types 2, 3, or 4). CK-2127107 is an investigational drug candidate designed for skeletal muscle and other debilitating neuromuscular…

SMA study Discussion

Biogen and Ionis Pharmaceuticals recently reported that nusinersen, an antisense drug designed to treat spinal muscular atrophy (SMA), ably met the primary endpoint set for an interim analysis of its Phase 3 ENDEAR clinical trial. That study, evaluating nusinersen as a treatment for infantile-onset (consistent with Type 1) SMA, is now closing and the program expanding…

Study representatives reported on the progress of six treatment approaches that are now in clinical trials for SMA. Discussion

Progress reports on six treatment options for spinal muscular atrophy (SMA), all currently in clinical trials, were spotlighted at the recent 2016 Annual SMA Conference in Anaheim, CA. The updates, provided by study representatives, shows that efforts are advancing toward new therapies for SMA. Four of the six treatment programs — AVXS-101, nusinersen, RG7800/RG7916, and…

Phase 1 trial of SMA gene therapy Discussion

AveXis presented positive pulmonary data from an interim analysis of its ongoing Phase 1 trial of AVXS-101 for the treatment of spinal muscular atrophy (SMA) type 1. The presentation, by Richard Shell, M.D., a member of the Section of Pulmonary Medicine at Nationwide Children’s Hospital, was made at the recent 2016 International Conference…